The Icelandic food products were developed in cooperation with the Icelandic research organisation Matis, and documented through both Nordic- (Ref. 1) and EU funded projects.
At observed intake levels up to about
5 g/d, consumption of marine omega-3
(EPA + DHA) has not been associated
with adverse effects in healthy
children or adults.
Studies included in the opinion report were;
Supplemental intakes of EPA and DHA consumed combined to doses up to about 5 g/d, do not induce changes in lipid peroxidation, which might raise concern in relation to cardiovascular disease (CVD) risk as long as the oxidative stability of these marine omega-3 (EPA + DHA) is guaranteed.
Long-term supplemental intakes of EPA and DHA combined up to about 5 g/d do not increase the risk of spontaneous bleeding episodes or bleeding complications even in subjects at high risk of bleeding (e.g. taking acetylsalicylic acid or anti-coagulants).
Supplemental intakes of EPA and DHA combined to doses up to 5 g/d do not significantly affect glucose homeostasis in healthy or diabetic subjects.
Supplemental intakes of EPA and DHA combined to doses up to 5 g/d do not induce changes in immune functions, which might raise concern in relation to the risk of infections or inappropriate activation of inflammatory responses.
- Emilía Martinsdóttir, Kolbrún Sveinsdóttir, Kyösti Pennanen, Raija-Liisa Heiniö, February 2014. Convenience Seafood Products. Nordic Innovation Publication 2014
- The scientific opinion of the European Food Safety Authority (EFSA) scientific panel, EFSA Journal 2012;10(7):2815.